SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories - Quaterly Results

31 Jan 2024 Evaluate
The company witnessed a 14.51% growth in the revenue at Rs. 3946.33 millions for the quarter ended December 2023 as compared to Rs. 3446.20 millions during the year-ago period.The Net Profit of the company vaulted to 180.11% to Rs. 352.02  millions from Rs. 125.67 millions in the previous quarter.Operating Profit saw a handsome growth to 547.74 millions from 226.34 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 3946.33 3446.20 14.51 11449.94 10023.59 14.23 13388.83 14492.67 -7.62
Other Income 36.58 11.87 208.17 85.80 27.70 209.75 57.59 102.35 -43.73
PBIDT 547.74 226.34 142.00 1142.60 649.09 76.03 830.29 1393.72 -40.43
Interest 20.44 5.50 271.64 27.82 14.19 96.05 19.81 -73.66 -126.89
PBDT 527.30 220.84 138.77 1114.78 634.90 75.58 810.48 1467.38 -44.77
Depreciation 55.08 45.57 20.87 152.11 133.92 13.58 180.06 211.95 -15.05
PBT 472.22 175.27 169.42 962.67 500.98 92.16 630.42 1255.43 -49.78
TAX 120.20 49.60 142.34 252.92 141.33 78.96 167.99 244.82 -31.38
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 2.03 24.83 -91.82
PAT 352.02 125.67 180.11 709.75 359.65 97.34 462.43 1010.61 -54.24
Equity 1022.27 1022.27 0.00 1022.27 1022.27 0.00 1022.27 955.59 6.98
PBIDTM(%) 13.88 6.57 111.33 9.98 6.48 54.10 6.20 9.62 -35.51

Morepen Laboratories Share Price

41.92 0.79 (1.92%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×